305 related articles for article (PubMed ID: 7692111)
21. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer.
Björk T; Piironen T; Pettersson K; Lövgren T; Stenman UH; Oesterling JE; Abrahamsson PA; Lilja H
Urology; 1996 Dec; 48(6):882-8. PubMed ID: 8973671
[TBL] [Abstract][Full Text] [Related]
22. The value of gamma-seminoprotein in combination with prostate specific antigen in detecting prostate cancer.
Nakashima J; Nagata H; Sumitomo M; Miyajima A; Tachibana M; Baba S; Jitsukawa S; Murai M
Int J Urol; 1999 Jun; 6(6):298-304. PubMed ID: 10404306
[TBL] [Abstract][Full Text] [Related]
23. Serum-to-urinary prostate-specific antigen ratio: a potential means of distinguishing benign prostatic hyperplasia from prostate cancer.
Irani J; Millet C; Levillain P; Doré B; Begon F; Aubert J
Eur Urol; 1996; 29(4):407-12. PubMed ID: 8791046
[TBL] [Abstract][Full Text] [Related]
24. Serum gamma-seminoprotein determination in prostatic cancer.
Shimazaki J; Akimoto S; Akakura K; Yoshiki T; Yoshida O; Okada K; Matsuoka K; Noda S; Eto K
Hinyokika Kiyo; 1991 Apr; 37(4):341-7. PubMed ID: 1716404
[TBL] [Abstract][Full Text] [Related]
25. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA.
Van Cangh PJ; De Nayer P; De Vischer L; Sauvage P; Tombal B; Lorge F; Wese FX; Opsomer R
Urology; 1996 Dec; 48(6A Suppl):67-70. PubMed ID: 8973703
[TBL] [Abstract][Full Text] [Related]
26. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
[TBL] [Abstract][Full Text] [Related]
27. Serum prostatic acid phosphatase, gamma-seminoprotein and prostatic specific antigen in hemodialysis patients.
Sasagawa I; Nakada T; Hashimoto T; Ishigooka M; Kubota Y; Hirano K; Hirano J; Suzuki Y
Urol Int; 1992; 48(2):181-3. PubMed ID: 1374977
[TBL] [Abstract][Full Text] [Related]
28. Optimum PSA reflex-range.
Benecchi L
Arch Ital Urol Androl; 2006 Jun; 78(2):44-8. PubMed ID: 16929601
[TBL] [Abstract][Full Text] [Related]
29. [Study of free to total prostate specific antigen ratio in the detection of patients with prostate cancer].
Ohuchi H; Mikata K; Miyoshi Y; Ohta J; Osada Y; Uemura H; Yao M; Takeda M; Noguchi S; Kubota Y; Hosaka M; Jinza S; Asakura T; Ebato T
Nihon Hinyokika Gakkai Zasshi; 2000 Dec; 91(12):695-9. PubMed ID: 11201129
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer.
Froehner M; Hakenberg OW; Koch R; Schmidt U; Meye A; Wirth MP
Urol Int; 2006; 76(1):27-30. PubMed ID: 16401917
[TBL] [Abstract][Full Text] [Related]
31. [Clinical study of tumor markers in prostatic carcinoma--an investigation on the simultaneous measurement of prostatic acid phosphatase (PAP), prostatic antigen (PA) and gamma-seminoprotein (gamma-Sm)].
Tsukamoto T; Kumamoto Y; Yamazaki K; Umehara T; Miyao N; Ohmura K; Iwazawa M
Hinyokika Kiyo; 1988 Jun; 34(6):987-95. PubMed ID: 2464917
[TBL] [Abstract][Full Text] [Related]
32. [Clinical studies of gamma-seminoprotein in prostatic disease. I. Clinical evaluation of serum gamma-seminoprotein].
Hasegawa S; Nakashima J; Nakashima Y; Nakamura S; Kimura S
Hinyokika Kiyo; 1987 Dec; 33(12):2055-8. PubMed ID: 3329453
[TBL] [Abstract][Full Text] [Related]
33. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
[TBL] [Abstract][Full Text] [Related]
34. Clinical evaluation of gamma-seminoprotein in prostate cancer.
Kuriyama M; Takeuchi T; Shinoda I; Okano M; Nishiura T
Prostate; 1986; 8(3):301-11. PubMed ID: 2422639
[TBL] [Abstract][Full Text] [Related]
35. Clinical evaluation of serum prostate-specific antigen-alpha1-antichymotrypsin complex values in diagnosis of prostate cancer: a cooperative study.
Kuriyama M; Ueno K; Uno H; Kawada Y; Akimoto S; Noda M; Nasu Y; Tsushima T; Ohmori H; Sakai H; Saito Y; Meguro N; Usami M; Kotake T; Suzuki Y; Arai Y; Shimazaki J
Int J Urol; 1998 Jan; 5(1):48-54. PubMed ID: 9535601
[TBL] [Abstract][Full Text] [Related]
36. [The significance of serum gamma-seminoprotein in prostatic cancer].
Ishikawa S; Tozuka K; Ishiyama S; Goto K; Ohba S; Tokue A; Yonese Y; Kamachi S; Sakurabayashi I; Kawai T
Hinyokika Kiyo; 1985 Jun; 31(6):961-7. PubMed ID: 2414979
[TBL] [Abstract][Full Text] [Related]
37. Prostate-specific antigen density values among patients with symptomatic prostatic enlargement in Nigeria.
Udeh EI; Nnabugwu II; Ozoemena FO; Ugwumba FO; Aderibigbe AS; Ohayi SR; Echetabu KN
World J Surg Oncol; 2016 Jun; 14(1):174. PubMed ID: 27356753
[TBL] [Abstract][Full Text] [Related]
38. Prostate-specific antigen (protein and mRNA) analysis in the differential diagnosis and staging of prostate cancer.
Castaldo G; Cecere G; di Fusco V; Prezioso D; d'Armiento M; Salvatore F
Clin Chim Acta; 1997 Sep; 265(1):65-76. PubMed ID: 9352130
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen (PSA) and cancer-associated serum antigen (CASA) in distinguishing benign and malignant prostate disease.
Devine PL; Walsh MD; McGuckin MA; Quin RJ; Hohn BG; Clague A; Samaratunga H
Int J Biol Markers; 1995; 10(4):221-5. PubMed ID: 8750649
[TBL] [Abstract][Full Text] [Related]
40. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations.
Gohji K; Nomi M; Egawa S; Morisue K; Takenaka A; Okamoto M; Ohori M; Fujii A
Cancer; 1997 May; 79(10):1969-76. PubMed ID: 9149025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
